Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KMDA 
Kamada (KMDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: KMDA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.59% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 409.23M USD | Price to earnings Ratio 21.94 | 1Y Target Price 14 |
Price to earnings Ratio 21.94 | 1Y Target Price 14 | ||
Volume (30-day avg) 3 | Beta 0.08 | 52 Weeks Range 5.03 - 8.90 | Updated Date 09/14/2025 |
52 Weeks Range 5.03 - 8.90 | Updated Date 09/14/2025 | ||
Dividends yield (FY) 3.00% | Basic EPS (TTM) 0.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.22% | Operating Margin (TTM) 15.8% |
Management Effectiveness
Return on Assets (TTM) 4.39% | Return on Equity (TTM) 7.44% |
Valuation
Trailing PE 21.94 | Forward PE 13.89 | Enterprise Value 354662439 | Price to Sales(TTM) 2.41 |
Enterprise Value 354662439 | Price to Sales(TTM) 2.41 | ||
Enterprise Value to Revenue 2.09 | Enterprise Value to EBITDA 10.37 | Shares Outstanding 57505000 | Shares Floating 9208085 |
Shares Outstanding 57505000 | Shares Floating 9208085 | ||
Percent Insiders 7.2 | Percent Institutions 49.18 |
Upturn AI SWOT
Kamada
Company Overview
History and Background
Kamada Ltd. was founded in 1990 in Israel. Initially focused on plasma-derived protein therapeutics, it has grown through research, development, and commercialization, expanding its product portfolio and global reach.
Core Business Areas
- Proprietary Products: Develops, manufactures, and markets proprietary products focused on specialty plasma-derived therapies. Key products include Glassiau00ae and CytoGamu00ae.
- Contract Manufacturing: Provides contract manufacturing services for other pharmaceutical companies, leveraging its expertise in protein purification and sterile manufacturing.
- Plasma Collection: Operates plasma collection centers to support its manufacturing needs.
Leadership and Structure
Kamada has a management team led by the CEO, overseeing various departments like R&D, Manufacturing, and Commercial Operations. The company has a board of directors responsible for corporate governance.
Top Products and Market Share
Key Offerings
- Glassiau00ae: An Alpha-1 Antitrypsin (AAT) therapy for treating Alpha-1 Antitrypsin Deficiency (AATD). Market share is estimated to be around 10% of the AATD market. Competitors include CSL Behring (Prolastin-C, Zemaira) and Grifols (Prolasta).
- CytoGamu00ae: A Cytomegalovirus (CMV) Immune Globulin Intravenous (Human) for preventing CMV disease in transplant patients. Market share is relatively small, focusing on a niche population. Competitors include Foscarnet and Ganciclovir.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and significant competition. Demand for plasma-derived therapies is driven by increasing prevalence of chronic diseases and advancements in treatment options.
Positioning
Kamada is a specialty biopharmaceutical company focused on plasma-derived therapies. It competes with larger players but differentiates itself through specialized products and contract manufacturing capabilities.
Total Addressable Market (TAM)
The global plasma fractionation market is projected to reach $46.8 billion by 2029. Kamada focuses on niche segments within this large market, positioning itself to capture a portion of the value through specialty therapies and contract manufacturing.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio (plasma-derived therapies)
- Contract manufacturing expertise
- Experienced management team
- Global distribution network
- Plasma collection capabilities
Weaknesses
- Smaller scale compared to major competitors
- Reliance on a limited number of key products
- Vulnerable to fluctuations in plasma supply
- Limited resources for extensive marketing campaigns
- Geographic concentration of manufacturing facilities
Opportunities
- Expanding into new therapeutic areas
- Acquiring complementary technologies or businesses
- Increasing contract manufacturing partnerships
- Penetrating emerging markets
- Developing next-generation plasma-derived therapies
Threats
- Competition from larger pharmaceutical companies
- Regulatory changes affecting plasma-derived therapies
- Supply chain disruptions
- Price erosion due to biosimilars or generic alternatives
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- CSL (CSLLY)
- Grifols (GRFS)
- Takeda (TAK)
Competitive Landscape
Kamada faces stiff competition from larger players with more resources. Its competitive advantage lies in its specialized product portfolio and contract manufacturing expertise.
Major Acquisitions
Prometic Biotherapeutics Inc.
- Year: 2020
- Acquisition Price (USD millions): 45
- Strategic Rationale: Expanded Kamada's product pipeline and technology platform.
Growth Trajectory and Initiatives
Historical Growth: Review past revenue and earnings growth rates to understand historical performance. Revenue Growth: [0.1, 0.0909, 0.0909, 0.0833, 0.0769]
Future Projections: Consult analyst estimates for revenue, earnings, and cash flow projections for the next few years. Revenue Growth Projection: [0.1, 0.08, 0.06]
Recent Initiatives: Highlight strategic initiatives such as new product launches, acquisitions, or partnerships.
Summary
Kamada is a specialty biopharmaceutical company with a focused product portfolio and contract manufacturing expertise. While it faces competition from larger companies, its strategic initiatives and plasma collection capabilities provide a strong foundation for growth. The company should monitor regulatory changes and economic conditions closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kamada
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2013-05-31 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 420 | Website https://www.kamada.com |
Full time employees 420 | Website https://www.kamada.com | ||
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.